The impact of renal denervation procedure on use of antihypertensive drugs in the real-life setting

References

• Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–1281.
   PubMed Web of Science ®Google Scholar
• Esler MD, Krum H, Sobotka PA, Symplicity HTN-2 Investigators, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–1909.,
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128(2):132–140.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Kandzari DE, O'Neill WW, et al. SYMPLICITY HTN-3 investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–1401.
   PubMed Web of Science ®Google Scholar
• Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens. 2016;34(8):1639–1647.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. Authors/task force members:. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. J Hypertens. 2018;36:1953–1204. Erratum in: J Hypertens 2019;37:226
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2018;71:e13–e115. Erratum in: Hypertension 2018;71:e140–e144
   PubMed Web of Science ®Google Scholar
• Esler M. Illusions of truths in the symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens. 2014;8(8):593–598.
   PubMed Web of Science ®Google Scholar
• Morganti A, Mancia G. Resistant hypertension: Renal denervation or intensified medical treatment? Eur J Intern Med. 2018;50:6–11.
   PubMed Web of Science ®Google Scholar
• Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the prague-15 study. Hypertension. 2015;65(2):407–413.
   PubMed Web of Science ®Google Scholar
• Azizi M, Sapoval M, Gosse P, Renal Denervation for Hypertension (DENERHTN) investigators, et al. Renal denervation for hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–1965.
   PubMed Web of Science ®Google Scholar
• Townsend RR, Mahfoud F, Kandzari DE, et al. SPYRAL HTN-OFF MED trial investigators*. catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–2170.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Böhm M, Mahfoud F, SPYRAL HTN-ON MED Trial Investigators, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–2355.
   PubMed Web of Science ®Google Scholar
• Azizi M, Sanghvi K, Saxena M, RADIANCE-HTN investigators, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476–2486.
   PubMed Web of Science ®Google Scholar
• Azizi M, Schmieder RE, Mahfoud F, RADIANCE-HTN Investigators, et al. RADIANCE-HTN investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–2345. Erratum in: Lancet. 2018;392:820
   PubMed Web of Science ®Google Scholar
• Böhm M, Kario K, Kandzari DE, SPYRAL HTN-OFF MED Pivotal Investigators, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451.
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Mancia G, Schmieder R, et al. Renal denervation in High-Risk patients With hypertension. J Am Coll Cardiol. 2020;75(23):2879–2888.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Mahfoud F, Mancia G, members of the ESH Working Group on Device-Based Treatment of Hypertension, et al. European society of hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733–1741.
   PubMed Web of Science ®Google Scholar
• Corrao G, Mancia G. Research strategies in treatment of hypertension: value of retrospective real-life data. Eur Heart J. 2022;43(35):3312–3322.
   PubMed Web of Science ®Google Scholar
• Rea F, Savaré L, Franchi M, et al. Adherence to treatment by initial antihypertensive Mono and combination therapies. Am J Hypertens. 2021;34(10):1083–1091.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Nasothimiou EG, Chang CL, ASCOT investigators, et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian cardiac outcome trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 2011;29(10):2004–2013.
   PubMed Web of Science ®Google Scholar
• Corrao G, Rea F, Di Martino M, et al. Developing and validating a novel multisource comorbidity score from administrative data: a large population-based cohort study from Italy. BMJ Open. 2017;7(12):e019503.
   PubMed Web of Science ®Google Scholar
• Jacoby WG. Loess: a nonparametric, graphical tool for depicting relationships between variables. Electoral Studies. 2000;19(4):577–613.
   Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American heart association professional education committee of the council for high blood pressure research. Hypertension. 2008;51(6):1403–1419.
   PubMed Web of Science ®Google Scholar
• Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976–990.
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932–934.
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Brambilla G, et al. Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. Hypertension. 2015;65(6):1209–1216.
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Böhm M, Schmieder R, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the global SYMPLICITY registry. Eur Heart J. 2019;40(42):3474–3482.
   PubMed Web of Science ®Google Scholar
• Ott C, Mahfoud F, Mancia G, et al. Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPLICITY registry with follow-up data of 3 years. Nephrol Dial Transplant. 2022;37(2):304–310.
   PubMed Web of Science ®Google Scholar
• Corrao G, Mancia G. Generating evidence from computerized healthcare utilization databases. Hypertension. 2015;65(3):490–498.
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency. National Reports on Medicines use in Italy. Year 2019. https://www.aifa.gov.it/documents/20142/241052/OsMed_2019_Eng.pdf. [Accessed 14 September 2022]
   Google Scholar
• Fengler K, Rommel KP, Blazek S, et al. A Three-Arm randomized trial of different renal denervation devices and techniques in patients With resistant hypertension (RADIOSOUND-HTN). Circulation. 2019;139(5):590–600.
   PubMed Web of Science ®Google Scholar
• Yang X, Liu H, Chen S, et al. Intravascular renal denervation reduces ambulatory and office blood pressure in patients with essential hypertension: a Meta-Analysis of randomized Sham-Controlled trials. Kidney Blood Press Res. 2022;47(6):363–374.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, Task Force Members, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC). J Hypertens. 2013;31(7):1281–1357.
   PubMed Web of Science ®Google Scholar